Get the Stockscreener App
11.21
2.86%
-0.33
After Hours:
11.00
-0.21
-1.87%
Mink Therapeutics Inc stock is traded at $11.21, with a volume of 11,201.
It is down -2.86% in the last 24 hours and down -2.01% over the past month.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
See More
Previous Close:
$11.54
Open:
$11.5
24h Volume:
11,201
Relative Volume:
0.04
Market Cap:
$55.85M
Revenue:
-
Net Income/Loss:
$-12.49M
P/E Ratio:
-3.781
EPS:
-2.9648
Net Cash Flow:
$-5.93M
1W Performance:
-5.08%
1M Performance:
-2.01%
6M Performance:
-17.94%
1Y Performance:
+51.90%
1-Day Range:
$11.00
$11.56
1-Week Range:
$11.00
$12.44
52-Week Range:
$6.34
$76.00
Mink Therapeutics Inc Stock (INKT) Company Profile
Name
Mink Therapeutics Inc
Sector
Industry
Phone
212-994-8250
Address
149 FIFTH AVENUE, NEW YORK
Compare INKT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
11.21 | 57.49M | 0 | -12.49M | -5.93M | -2.9648 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-14-25 | Downgrade | William Blair | Outperform → Mkt Perform |
Mink Therapeutics Inc Stock (INKT) Latest News
MiNK Therapeutics | DEF 14A: Definitive information statements - Moomoo
Board elections and auditor vote at MiNK Therapeutics (NASDAQ: INKT) - Stock Titan
Director Holcomb of MiNK Therapeutics (NASDAQ: INKT) receives 4,174 stock options grant - Stock Titan
MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Short Interest in MiNK Therapeutics, Inc. (NASDAQ:INKT) Drops By 30.6% - MarketBeat
Trading Systems Reacting to (INKT) Volatility - Stock Traders Daily
MiNK outlines initial ARDS phase II data in H2 2026 while extending runway through 2026 - MSN
MiNK Therapeutics (NASDAQ:INKT) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Buy Rating on MiNK Therapeutics Driven by Promising Phase 2 Survival Benefit and Immune Activation in PD-1–Refractory Gastric Cancer - TipRanks
INKT MiNK Therapeutics posts narrower Q4 2025 loss than expected, shares drop 9.78 percent on zero revenue. - Cổng thông tin điện tử Tỉnh Sơn La
MiNK Therapeutics (INKT) Stock Rights Issue (Weakens) 2026-04-22Professional Trade Ideas - UBND thành phố Hải Phòng
MiNK Therapeutics (INKT) Stock: Downside Risk (Crashes) 2026-04-20Real Time Stock Idea Network - Cổng thông tin điện tử tỉnh Lào Cai
Agenus cancer cocktail records 0% response rate, missing midstage goal - BioSpace
MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer - Sahm
Melissa Orilall Net Worth (2026) - GuruFocus
In hard-to-treat gastroesophageal cancer, some patients lived 20+ months - Stock Titan
How Mink Therapeutics Inc. (INKT) Affects Rotational Strategy Timing - Stock Traders Daily
INKT SEC FilingsMink Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
The INKT Cell Story: Why Investors Need To Watch MiNK Therapeutics Closely - RTTNews
H.C. Wainwright Maintains MiNK Therapeutics(INKT.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
Retail Surge: What is MiNK Therapeutics Incs P E ratio telling us2026 Top Gainers & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Smart Money: Whats the fair value of MiNK Therapeutics Inc stockWeekly Stock Summary & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
MiNK Therapeutics (INKT) finance officer reports 222 indirect shares on Form 3 - Stock Titan
Acute Respiratory Distress Syndrome Clinical Trial Pipeline Shows Potential with Active Contributions from 40+ Key Companies | DelveInsight - Dailyhunt
Fed Meeting: What is the target price for MiNK Therapeutics Inc stock2026 Key Highlights & Fast Entry High Yield Tips - baoquankhu1.vn
MiNK Therapeutics – Three Weeks. Three Catalysts - Oncodaily
INKT PE Ratio & Valuation, Is INKT Overvalued - Intellectia AI
Could a short squeeze happen in MiNK Therapeutics (INKT) Stock | INKT Q4 Earnings: Beats Estimates by $0.28Rating Downgrade - Cổng thông tin điện tử Tỉnh Sơn La
MiNK Therapeutics clarifies status of potential combination trials and investments By Investing.com - Investing.com
Will MiNK Therapeutics (INKT) Stock Hit Record Highs | Price at $11.96, Up 11.93%Bearish Pattern - Xã Thanh Hà
New Phase II Data on BOT/BAL Combination in Gastroesophageal Cancer at AACR 2026Agenus - Oncodaily
(INKT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
MiNK Therapeutics, Inc. (INKT) Stock Price, News, Quote & History - Yahoo! Finance Canada
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study on agenT-797 with Checkpoint Inhibitors for PD-1 Refractory Gastroesophageal Cancer at AACR 2026 - geneonline.com
Agenus Announces Data from Phase II Study of BOT+BAL in Combinati - The National Law Review
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026 - Investing News Network
HC Wainwright Issues Positive Outlook for INKT Earnings - MarketBeat
MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy - Sahm
MiNK AACR study targets gastroesophageal cancer after PD-1 failure - Stock Titan
MiNK Therapeutics' AgenT-797 Abstract Accepted for Presentation at ASGCT Annual Meeting 2026 - Quiver Quantitative
MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of ... - Caledonian Record
MiNK Therapeutics’ (INKT) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society 2026 International Conference - Investing News Network
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference - The Manila Times
MiNK Therapeutics Announces Abstract Acceptance for - GlobeNewswire
Mink Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum - Investing News Network
MiNK Therapeutics’ Earnings Call Signals High-Risk Upside - TipRanks
Earnings Call Summary | MiNK Therapeutics(INKT.US) Q4 2025 Earnings Conference - Moomoo
Mink Therapeutics Inc Stock (INKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):